Inflammation following ischemic brain injury is correlated with adverse outcome. Preclinical studies indicate that treatment with acetylsalicylic acid + extended-release dipyridamole (ASA + ER-DP) has anti-inflammatory and thereby neuroprotective effects by inhibition of monocyte chemotactic protein-1 (MCP-1) expression. We hypothesized that early treatment with ASA + ER-DP will reduce levels of MCP-1 also in patients with ischemic stroke. The EARLY trial randomized patients with ischemic stroke or TIA to either ASA + ER-DP treatment or ASA monotherapy within 24 h following the event. After 7 days, all patients were treated for up to 90 days with ASA + ER-DP. MCP-1 was determined from blood samples taken from 425 patients on admission and day 8. The change in MCP-1 from admission to day 8 did not differ between patients treated with ASA + ER-DP and ASA monotherapy ( p > 0.05). Comparisons within MCP-1 baseline quartiles indicated that patients in the highest quartile (>217–973 pg/mL) showed improved outcome at 90 days if treated with ASA + ER-DP in comparison to treatment with ASA alone ( p = 0.004). Our data does not provide any evidence that treatment with ASA + ER-DP lowers MCP-1 in acute stroke patients. However, MCP-1 may be a useful biomarker for deciding on early stroke therapy, as patients with high MCP-1 at baseline appear to benefit from early treatment with ASA + ER-DP.
References
[1]
Mergenthaler, P.; Dirnagl, U.; Meisel, A. Pathophysiology of stroke: Lessons from animal models. Metab. Brain Dis 2004, 19, 151–167.
[2]
Rodríguez-Yá？ez, M.; Castillo, J. Role of inflammatory markers in brain ischemia. Curr. Opin. Neurol 2008, 21, 353–357.
[3]
Worthmann, H.; Tryc, A.B.; Goldbecker, A.; Ma, Y.T.; Tountopoulou, A.; Hahn, A.; Dengler, R.; Lichtinghagen, R.; Weissenborn, K. The temporal profile of inflammatory markers and mediators in blood after acute ischemic stroke differs depending on stroke outcome. Cerebrovasc. Dis 2010, 30, 85–92.
[4]
Welsh, P.; Barber, M.; Langhorne, P.; Rumley, A.; Lowe, G.D.; Stott, D.J. Associations of inflammatory biomarkers with poor outcome in acute ischaemic stroke. Cerebrovasc. Dis 2009, 27, 247–253.
Chen, Y.; Hallenbeck, J.M.; Ruetzler, C.; Bol, D.; Thomas, K.; Berman, N.E.; Vogel, S.N. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J. Cereb. Blood Flow Metab 2003, 23, 748–755.
[7]
Justicia, C.; Panes, J.; Sole, S.; Cervera, A.; Deulofeu, R.; Chamorro, A.; Planas, A.M. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J. Cereb. Blood Flow Metab 2003, 23, 1430–1440.
Suzuki, S.; Sugai, K.; Sato, H.; Sakatume, M.; Arakawa, M. Inhibition of active oxygen generation by dipyridamole in human polymorphonuclear leukocytes. Eur. J. Pharmacol 1992, 227, 395–401.
[10]
Chakrabarti, S.; Vitseva, O.; Iyu, D.; Varghese, S.; Freedman, J.E. The effect of dipyridamole on vascular cell-derived reactive oxygen species. J. Pharmacol. Exp. Ther 2005, 315, 494–500.
[11]
Chakrabarti, S.; Freedman, J.E. Dipyridamole, cerebrovascular disease, and the vasculature. Vasc. Pharmacol 2008, 48, 143–149.
[12]
Al-Bahrani, A.; Taha, S.; Shaath, H.; Bakhiet, M. TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. Curr. Neurovasc. Res 2007, 4, 31–37.
[13]
Hallevi, H.; Hazan-Halevy, I.; Paran, E. Modification of neutrophil adhesion to human endothelial cell line in acute ischemic stroke by dipyridamole and candesartan. Eur. J. Neurol 2007, 14, 1002–1007.
Conductier, G.; Blondeau, N.; Guyon, A.; Nahon, J.L.; Rovère, C. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. J. Neuroimmunol 2010, 224, 93–100.
[16]
Hughes, P.M.; Allegrini, P.R.; Rudin, M.; Perry, V.H.; Mir, A.K.; Wiessner, C. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J. Cereb. Blood Flow Metab 2002, 22, 308–317.
[17]
Strecker, J.K.; Minnerup, J.; Gess, B.; Ringelstein, E.B.; Sch？bitz, W.R.; Schilling, M. Monocyte chemoattractant protein-1-deficiency impairs the expression of IL-6, IL-1β and G-CSF after transient focal ischemia in mice. PLoS One 2011, 6, e25863.
[18]
Dimitrijevic, O.B.; Stamatovic, S.M.; Keep, R.F.; Andjelkovic, A.V. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. Stroke 2007, 38, 1345–1353.
[19]
Kim, H.H.; Liao, J.K. Translational therapeutics of dipyridamole. Arterioscler. Thromb. Vasc. Biol 2008, 28, s39–s42.
[20]
Guo, S.; Stins, M.; Ning, M.; Lo, E.H. Amelioration of inflammation and cytotoxicity by dipyridamole in brain endothelial cells. Cerebrovasc. Dis 2010, 30, 290–296.
[21]
García-Bonilla, L.; Sosti, V.; Campos, M.; Penalba, A.; Boada, C.; Sumalla, M.; Hernández-Guillamon, M.; Rosell, A.; Montaner, J. Effects of acute post-treatment with dipyridamole in a rat model of focal cerebral ischemia. Brain Res 2011, 1373, 211–220.
[22]
Dengler, R.; Diener, H.C.; Schwartz, A.; Grond, M.; Schumacher, H.; Machnig, T.; Eschenfelder, C.C.; Leonard, J.; Weissenborn, K.; Kastrup, A.; et al. EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): A randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010, 9, 159–166.
[23]
Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects. Proceeding of 48th World Medical Association General Assembly, Somerset West, South Africa, 22–26 October, 1996; Available online: http://www.wma.net/en/30publications/10policies/b3/index.html , accessed on 1 May 2012.
[24]
Guideline for Good Clinical Practice E6(R1). International Conference on Harmonisation Harmonised Tripartite Guideline, 1996. Available online: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf , accessed on 1 May 2012.
